Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 16/20 | 0.83 |
| ▸ | FKBP5 | Q13451 | 3/20 | 0.83 |
| ▸ | FKBP2 | P26885 | 1/20 | 0.83 |
| ▸ | FKBP1B | P68106 | 1/20 | 0.83 |
| ▸ | FKBP3 | Q00688 | 1/20 | 0.83 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16937368 | 1.00 | FKBP1A (0.83) | FKBP1AFKBP5FKBP2FKBP1BFKBP3 | |
| SCHEMBL19594696 | 1.00 | FKBP1A (0.83) | FKBP1AFKBP5FKBP2FKBP1BFKBP3 | |
| SCHEMBL18354017 | 1.00 | FKBP1A (0.83) | FKBP1AFKBP5FKBP2FKBP1BFKBP3 | |
| SCHEMBL16938952 | 0.91 | FKBP1A (0.80) | FKBP1AFKBP5FKBP2FKBP1BFKBP3 | |
| SCHEMBL16937341 | 0.91 | FKBP1A (0.80) | FKBP1AFKBP5FKBP2FKBP1BFKBP3 | |
| SCHEMBL18354147 | 0.91 | FKBP1A (0.80) | FKBP1AFKBP5FKBP2FKBP1BFKBP3 | |
| SCHEMBL18354620 | 0.91 | FKBP1A (0.80) | FKBP1AFKBP5FKBP2FKBP1BFKBP3 | |
| SCHEMBL16937330 | 0.91 | FKBP1A (0.80) | FKBP1AFKBP5FKBP2FKBP1BFKBP3 | |
| SCHEMBL16948808 | 0.91 | FKBP1A (0.80) | FKBP1AFKBP5FKBP2FKBP1BFKBP3 | |
| SCHEMBL16949299 | 0.91 | FKBP1A (0.80) | FKBP1AFKBP5FKBP2FKBP1BFKBP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914732-B2 | Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V. (DE) | 2018-03-13 | — | — | US | disclosed |
| EP-3097103-B1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS (DE) | 2017-11-15 | — | — | EP | disclosed |
| US-20170002003-A1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V. (DE) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002003-A1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | SNCA, DDT, DRD1 | FKBP1A 297/4885FKBP5 255/4885FKBP2 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.